Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05632861 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)

StatusUnknown
PhasePhase 2
Started2023-02-21
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 29, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06
Trial status changed: Recruiting → Unknown
2024-08-28
Study Status v2
Trial statusRecruiting→Unknown
2023-08-07
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2022-11-30→confirmed 2023-02-21
Study sites20 entries, revised
ShiyanThe renminFirst hospitalAffiliated Hospital of Henan University of Science and Technology
2022-11-20
Original filing
This study will evaluate the efficacy and safety and the best effective dose of HuHuangLianzonggan capsule in subjects with nonalcoholic steatohepatitis.
Trial Details
NCT Number NCT05632861
Lead Sponsor Tasly Pharmaceutical Group Co., Ltd
Conditions NASH
Enrollment 76 participants
Start Date 2023-02-21
Primary Completion 2024-12-31 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-29